EZH2 and posterior cortical atrophy: In a recent study, silibinin administration at concentrations of 25–75 μg/mL for 48 h was shown to reduce the expression levels of enhancer of zeste homolog 2 (EZH2), embryonic ectoderm development (EED), and suppressor of zeste homolog 12 (SUZ12), in DU145 and PC3 PCa cells.